Gynecologic Cancer Trials
Every treatment that has ever made a difference in cancer care was once a part of a clinical trial. MUSC Hollings Cancer Center is committed to offering the best treatments available today while searching for even better ones for the future. Ask your doctor if a clinical trial is right for you.
STUDY26334
A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors
To determine the RP2D of DB-1311 in combination with BNT327 by assessing the safety and tolerability in targeted participant populations. To determine the RP2D of DB-1311 in combination with DB-1305 by assessing the safety and tolerability in targeted participant populations.
Study InformationSTUDY26716
An Open-Label, Sponsor-Blinded, Randomized, Controlled, Multicenter, Phase III Study of Trastuzumab Deruxtecan (T-DXd) Plus Rilvegostomig or Pembrolizumab vs Chemotherapy Plus Pembrolizumab as First-Line Therapy of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR), Primary Advanced or Recurrent Endometrial Cancer.
To demonstrate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd + pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment of progression free survival (PFS), as assessed by blinded independent central review (BICR), in participants with HER2-expressing (IHC 3+/2+), pMMR, primary advanced (Stage III/IV) or recurrent EC.
Study InformationSTUDY26995
A Phase 1a/1b Study of NRM-823 as Monotherapy and in Combination with Immune Checkpoint Inhibition in Participants with Locally Advanced or Metastatic Refractory Solid Tumors
To determine the safety and tolerability of NRM-823 as monotherapy and in combination with pembrolizumab in participants with advanced solid tumors. To determine the recommended dose(s) for expansion (RDE)s of NRM-823 as monotherapy and in combination with pembrolizumab in participants with advanced solid tumors. The RDE may be the maximum tolerated dose (MTD) or a biologically active dose below the MTD.
Study Information